Alimera Sciences Inc. is ready to launch in the US its recently approved intravitreal implant, Iluvien, for treating diabetic macular edema. President and CEO Dan Myers reported the company has a direct sales force of 32 reps ready for the product’s commercial debut in Q1 2015. Iluvien delivers a corticosteroid, providing sustained therapeutic effect for up to three years with one injection/implantation.
Dan Myers is the Co-Founder, President, and CEO of Alimera Sciences, Inc. Under Dan’s leadership Alimera has commercially launched ILUVIEN®, Alimera’s lead product, in the US, UK, Germany and Portugal with Marketing Authorizations in an additional 14 countries throughout the EU.